Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects

Saved in:

Bibliographic Details
Main Authors:	Qinglin Shen, Hexiao Tang, Shengxi Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Oncology
Subjects:	EGFR-TKIs development side effects application lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1617788/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma
by: Pritsana Raungrut, et al.
Published: (2025-06-01)

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models
by: Ilaria Marrocco, et al.
Published: (2021-03-01)

The correlation of HLA-A in Thai EGFR-mutated advanced non-small cell lung cancer, outcome, and tumor microenvironment
by: Nicha Zungsontiporn, et al.
Published: (2025-08-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes
by: Meng Zhang, et al.
Published: (2025-08-01)

Real-world comparative outcomes of EGFR-TKIs for first-line treatment of EGFR+ metastatic non–small-cell lung cancer
by: Kibum Kim, et al.
Published: (2025-01-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

Combination therapy of TKIs and ICIs for the treatment of anaplastic thyroid carcinoma
by: Xi Zhang, et al.
Published: (2025-05-01)

A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis
by: Jinyu Yu, PhD, et al.
Published: (2025-09-01)

EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study
by: Chao Zuo, et al.
Published: (2025-05-01)

EGFR-mutant lung adenocarcinoma transformed into small cell Lung cancer: A case report and literatures review
by: Jinhong Chen, et al.
Published: (2025-01-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

Case Report: A Bilateral Synchronous Primary Non‐Small Cell Lung Cancer Patient With Two Different EGFR Mutations
by: Thanh‐Dung Quach, et al.
Published: (2025-08-01)

De Novo EGFR ‐ALK and EGFR ‐ROS1 Co‐Mutations in NSCLC: Clinical Characteristics, Molecular Profiling, and Treatment Outcomes From a Retrospective Analysis
by: Lili Shen, et al.
Published: (2025-08-01)

Analysis and characterization of chondroitin/dermatan sulfate composition of lung adenocarcinoma tissues with different types of genetic alterations in ALK, EGFR and KRAS oncogenes
by: Domonkos Pál, et al.
Published: (2025-06-01)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
by: Azhar Ali, et al.
Published: (2018-02-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions
by: Yang Li, et al.
Published: (2025-04-01)

Triple reversal phenomenon in EGFR-mutant lung adenocarcinoma with prostate metastasis following hepatocellular carcinoma: a rare Case Report with diagnostic and therapeutic implications
by: Jieyan Luo, et al.
Published: (2025-07-01)

Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21 L858R mutation
by: Yan’e Liu, et al.
Published: (2025-06-01)

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer
by: Yongfeng Yu, et al.
Published: (2025-07-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
by: Kimio Yonesaka, et al.
Published: (2025-03-01)

Accessing utility of immunohistochemistry, PD-L1 correlation with stage of cancer and EGFR mutation with disease survival in primary lung carcinoma
by: Kartavya Kumar Verma, et al.
Published: (2025-06-01)

RESULTS OF TREATMENT OF PATIENTS WITH LOCALLY ADVANCED AND METASTATIC NON-SQUAMOUS CELL NON-SMALL-CELL LUNG CARCINOMA WITH PEMETREXED (BY OWN EXPERIENCE)
by: L. Yu. Vladimirova, et al.
Published: (2016-04-01)

Systematic identification of proteins that elicit drug side effects
by: Michael Kuhn, et al.
Published: (2013-04-01)

The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer
by: Maciej Pawel Jankowski, et al.
Published: (2025-01-01)

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer
by: Lingbo Bao, et al.
Published: (2025-08-01)

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study
by: Xiaochun Chen, et al.
Published: (2025-07-01)

The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
by: Olivier Calvayrac, et al.
Published: (2016-12-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

A Case of Lung Cancer Exhibiting Pleoymorphic Carcinoma Transformation Resistance Following Treatment With Osimertinib That Was Successfully Treated Using Local Ablative Treatment
by: Yoshiaki Nagai, et al.
Published: (2025-01-01)

Ethyl acetate extract of Ruta graveolens: a specific and potent inhibitor against the drug-resistant EGFR_T790M mutant in NSCLC
by: Vikas Kumar, et al.
Published: (2025-04-01)

Circulating Tumour DNA in Patients With EGFR‐Mutated Non‐Small‐Cell Lung Cancer and Early Disease Progression After First‐Line Osimertinib Treatment: The ELUCIDATOR Multicentre Prospective Observational Study
by: Akihiro Tamiya, et al.
Published: (2025-04-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

Cudratricusxanthone A exhibits antitumor activity and enhances chemosensitivity to cisplatin against NSCLC via targeting EGFR
by: Peiyuan Sun, et al.
Published: (2025-08-01)

Side Effects of Steroidal And Non-Steroidal Anti-Inflammatory Drugs on The Oral Cavity.
by: Shayma Ghazi, et al.
Published: (2024-03-01)

Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway
by: Hyun-Ha Hwang, et al.
Published: (2025-07-01)

Mental Health Consequences of COVID‐19 Vaccine Side Effects: Findings From a Cross‐Sectional Analysis
by: Md. Shajadul Islam, et al.
Published: (2025-07-01)